References
- Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs (erratum in Lancet 1994;343:1048). Lancet 1994;343:769-72
- Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55
- Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26 (Suppl 56):18-24
- Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med 1992;34:507-13
- Scholes D, Stergachis A, Penna PM, et al. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol 1995;22:708-12
- Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 1992;45:187-95
- Goupille P, Logeart I, Combe B. Naturalistic survey on nonsteroidal antiinflammatory treatment in patients with musculoskeletal pain. Joint Bone Spine 2003;70:219-25
- Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000;27:1876-83
- Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11
- McKenna F, Arguelles L, Burke T, et al. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp Rheumatol 2002;20:35-43
- Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports (erratum in Arthritis Res Ther 2006;8:401). Arthritis Res Ther 2005;7:R644-65
- Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119:255-66
- White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007;99:91-8
- US Food and Drug Administration. Advisory Committee Briefing Document: Celecoxib and Valdecoxib Cardiovascular Safety. FDA. Available at: www.fda.gov/ohrms/dockets//ac/05/briefing/2005-4090B1_03_Pfizer-Celebrex-Bextra.pdf. [Last accessed 27 October 2008]
- PhRMA Clinical Study Synopsis, CLASS Study, 2006. Clinical Study Results Web site. Available at: http://www.clinicalstudyresults.org/documents/company-study_1841_0.pdf. [Last accessed 30 April 2008]
- Goldstein JL, Eisen GM, Burke TA, et al. Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther 2002;16:819-27
- Wolfe F, Michaud K, Burke TA, et al. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol 2004;31:355-8
- Zhao SZ, Wentworth C, Burke TA, et al. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 2004;13:277-87